U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Col	Complete if Known		
	Application Number	10/593,407		
INFORMATION DISCLOSURE	Filing Date	September 19, 2006		
	First Named Inventor	David P. Fairlie		
STATEMENT BY APPLICANT	Art Unit	1654		
(Use as many sheets as necessary)	Examiner Name	Julie Ha		
noot 1	Attorney Docket Number	23558-023USNATI		

	· · · · · · · · · · · · · · · · · · ·			<u> DOCUMENTS</u>		
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (d known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Wher Relevant Passages or Relevan Figures Appear	
-	A1	^{US-} 5,149,779	09-22-1992	Chorev, et al.		
	A2	^{US-} 5,364,851	11-15-1994	Alvin D. Joran		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
***************************************		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

		FORE	GN PATENT DOCL	IMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
		WO 00/001730	01-13-2000	A+ Science Invest AB		
		WO 04/067021	08-12-2004	Gardella, et al.		
		WO 95/031480	11-23-1995	S.P.I. Synthetic Peptides		
		WO 97/042223	11-13-1997	The Admin. of the Tulane		
			-			

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

	Olider the rap	JCI WOIK	recurrence Act of 1775, no persons are require	ta to respond to a concentor of	information timess it contains a valid Olvid control number.
Substitute fo	Substitute for form 1449/PTO		Complete if Known		
5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5				Application Number	10/593,407
	INFORMATI	ION	DISCLOSURE	Filing Date	September 19, 2006
STATEMENT BY APPLICANT (Use as many sheets as necessary) (Use as many sheets as necessary)				First Named Inventor	David P. Fairlie
				Art Unit	1654
				Examiner Name	Julie Ha
Sheet	2	of	5	Attorney Docket Number	23558-023USNATL

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium,	T-
Initials*	No.1	catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	B1	Barlow, D.J.: Thornton. J. M. J. Mol. Biol. 1988, 201,601	
	B2	Fairlie, D.; West, M.; Wong, A. Curr. Med. Chem. 1998, 5, 29	
	B3	Andrews, M. J. I.; Tabor, A. B. Tetrahedron 1999, 55, 11711	
	B4	Kussie, P. H.; Gorina, S.; Marechal, V.: Elenbaas, B.; Moreau, J.; <i>Science</i> 1996, 274, 948-953	
	B5	Burley, S. K.; Roeder, R.G. Ann. Rev. Biochem. 1996. 65, 769	
	B6	Uesugi, M.; Nyaguile, O.; Lu, H.; Levine, A. J.; Verdine, G. L. Science 1997, 277, 1310	
	B7	Sattler, M.; Liang, H.; Nettesheim, D.; Meadows, R. P.; Harlan, J. E.; Eberstadt, M.; Yoon, H. S.; Shuker, S. B.; Chang, B. S.; Minn, A. J.; Thompson, C. B.; Fesik, S. W. <i>Science</i> 1997, 275, 983-986.	
	B8	Tan, R.; Chen, L.; Buettner, J.A.; Hudson, D.; Frankel, A.D. Cell 1993, 73, 1031.	
	В9	Pabo, C. O.; Peisach, E.; Grant, R. A. Annual Review of Biochemistry 2001, 70, 313-340	
	B10	Weiss, M. A.; Narayana, N. Biopolymers 1998, 48, 167-180	
	B11	Botuyan, M. V.; Mer, G.; Yi, G.; Koth, C. M.; Case, D. A.; Edwards, A. M.; Chazin, W. J.; Arrowsmith, C. H. J. Mol. Biol. 2001, 312, 177-186	
	B12	Uesugi, M.; Nyanguile, O.; Lu, H.; Levine, A. J.; Verdine, G. L. Science 1997, 277, 1310-1313	
	B13	Jin, L.; Briggs, S. L.; Chandrasekhar, S.; Chirgadze, N. Y.; Clawson, D. K.; Scheivitz, R. W.; Smiley, D. L.; Tashjian, A. H.; Zhang, F. <i>Journal of Biological Chemistry</i> 2000, 275, 27238-27244	
	B14	Schwyzer, R. <i>Biochemistry</i> 1986 , 25, 4281-4286	
	B15	Bennett, M. A.; Murray, T. F.; Aldrich, J. V. Journal of Medicinal Chemistry 2002, 45, 5617-5619	
	B16	Zaiou, M. Z.; Arnold, K. S.; Newhouse, Y. M.; Innerarity, T. L.; Weisgraber, K. H.; Segall, M. L.; Phillips, M. C.; Lund-Katz, <i>S. Journal of Lipid Reseach</i> 2000 , 41, 1087-1095	
	B17	Kirby, D. A.; Koerber, S. C.; Craig, A. G.; Feinstein, R. D.; Delmas, L.; Brown, M. R.; Rivier, J. E. <i>Journal of Medicinal Chemistry</i> 1993 , <i>36</i> , 385-393	
	B18	Carpenter, K. A.; Schmidt, R.; Yue, S. Y.; Hodzic, L.; Pou, C.; Payza, K.; Godbout, C.; Brown, W.; Roberts, E. <i>Biochemistry</i> 1999 , <i>38</i> , 15295-15304	
	B19	Miranda, A.; Lahrichi, S. L.; Gulyas, J.; Koerber, S. C.; Craig, A. G.; Corrigan, A.; Rivier, C.; Vale, W.; Rivier, J. Journal of Medicinal Chemistry 1997, 40, 3651-3658	
	B20	Li, J. Z.; Matsuura, J. E.; Waugh, D. J. J.; Adrian, T. E.; Abel, P. W.; Manning, M. C.; Smith, D. D. Journal of Medicinal Chemistry 1997, 40, 3071-3076	
	B21	Nicole, P.; Lins, L.; Rouyer-Fessard, C.; Drouot, C.; Fulcrand, P.; Thomas, A.; Couvineau, A.; Martinez, J.; Brasseur, R.; Laburthe, M. <i>J Biol Chem</i> 2000 , 275, 24003-24012	
	B22	McInerney, E. M.; Rose, D. W.; Flynn, S. E.; Westin, S.; Mullen, T. M.; Krones, A.;	

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	abstitute for form 1449/PTO		teduction rect of 1999, no persons are requi	Complete if Known		
Substitute to	31 101111 144 <i>3</i> /1 10			Application Number	10/593,407	
	INFORMATI	ON I	DISCLOSURE	Filing Date	September 19, 2006	
STATEMENT BY APPLICANT				First Named Inventor	David P. Fairlie	
			ALLEGAN	Art Unit	1654	
(Use as many sheets as necessary) (Use as many sheets as necessary)			ts as necessary)	Examiner Name	Julie Ha	
Sheet	3		5	Attorney Docket Number	23558-023USNATL	

NON PATENT LITERATURE DOCUMENTS

	Inostroza, J.; Torchia, J.; Nolte, R. T.; Assa-Mont, N.; Milburn, M. V.; Glass, C. K.;	
	Rosenfeld, M. G. Genes Dev 1998, 12, 3357-3368	
B23	Chang, C.; Norris, J. D.; Gron, H.; Paige, L. A.; Hamilton, P. T.; Kenan, D. J.;	
	Fowlkes, D.; McDonnell, D. P. Mol Cell Biol 1999, 19, 8226-8239	
B24	Zimm, B.; Bragg, J. J. Chem. Phys. 1959, 31, 526	
B25	Scholtz, A.; Baldwin, R. L. Annu. Rev. Biophys. Biomol. Struct. 1992, 21, 95	
B26	Kemp, D.; Curran, T.; Boyd, J.; Allen, T. J. Org. Chem. 1991, 56, 6683	
B27	Muller, K.; Obrecht, D.; Knierzinger, A.; Stankovic, C.; Spiegler, C.; Bannwarth, W.;	
	Trzeciak, A.; Englert, G.; Labhardt, A. M.; Schoenholzer, P. Perspect. Med. Chem.	
	1993, 513	
B28	Austin, R.; Maplestone, R. A.; Sefler, A. M.; Liu, K.; Hruzewicz, W. N.; Liu, C.; Cho,	
	H. S.; Wemmer, D. E.; Bartlett, P. A. J. Am. Chem. Soc. 1997, 119, 6461	
B29	Aurora, R.; Rose, G. D. Protein Science 1998, 7, 21	
B30	Ghadiri, M. R.; Choi, C. J. Am. Chem. Soc. 1990, 112, 1630	
B31	Ruan, F.; Chen, Y.; Hopkins, P. B. J. Am. Chem. Soc. 1990, 112, 9403	
B32	Ghadiri, M. R.; Fernholz, H. J. Am. Chem. Soc. 1990, 112, 9633	
B33	Kohn, W. D.; Kay, C. M.; Sykes, B. D.; Hodges, R. S. J. Am. Chem. Soc. 1998, 120,	
	1124	
B34	Kelso, M. J.; Hoang, H.; Appleton, T. G.; Fairlie, D. P. J. Am. Chem. Soc. 2000, 122, 10488	
B35	Kelso, M. J.; Hoang, H. N.; Oliver, W. N.; Sokolenko, N.; March, D. R.; Appleton, T.	
	G.; Fairlie, D. P. Angew Chem, Int. Edit. 2003, 42, 421-424	
B36	Rajashankar, K. R.; Ramakumar, S.; Jain, R. M.; Chauhan, V. S. J. Am. Chem. Soc.	
	1995, <i>117</i> , 10129	
B37	Karle, I. L.; Balaram, P. Biochem. 1990, 29, 6747	
B38	Mayne, L.; Englander, S. W.; Qiu, R.; Yang, J.; Gong, Y.; Spek, E. J.; Kallenbach, N. R.	
	J. Am. Chem. Soc. 1998, 120, 10643	
B39	Albert, J. S.; Hamilton, A. Biochem. 1995, 34, 984	
B40	Pellegrini, M.; Royo, M.; Chorev, M.; Mierke, D. F. J. Pep. Res. 1997, 49, 404	
B41	Jackson, D. Y.; King, D. S.; Chmielewski, J.; Singh, S.; Schultz, P. G. J. Am. Chem. Soc. 1991, 113, 9391	
B42	Cabezas, E.; Satterthwait, A. C. J. Am. Chem. Soc. 1999, 121, 3862	
B43	Taylor, J. W. Biopolymers 2002, 66, 49	
B44	Schievano, E.; Mammi, S.; Bisello, A.; Rosenblatt, M.; Chorev, M.; Peggion, E. J.	
	Pept. Sci. 1999, 5, 330	
B45	Bracken, C.; Gulyas, J.; Taylor, J. W.; Baum, J. J. Am. Chem. Soc. 1994, 116, 6431	
B46	Phelan, J. C.; Skelton, N. J.; Braisted, A. C.; McDowell, R. S. J. Am. Chem. Soc. 1997,	
	119, 455. (e) Taylor, J. W.; Yu, C. Bioorg. Med. Chem. 1999, 7, 161	
B47	Chen, ST.; Chen, HJ.; Yu, HM.; Wang, KT. J. Chem. Res. (S) 1993, 228	

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	Onder the rap	JCI WOLK	Reduction Act of 1993, no persons are require	ed to respond to a confection of	information timess it contains a valid ONE control number.	
Substitute fo	bstitute for form 1449/PTO			Complete if Known		
				Application Number	10/593,407	
	INFORMAT	ION	DISCLOSURE	Filing Date	September 19, 2006	
STATEMENT BY APPLICANT				First Named Inventor	David P. Fairlie	
				Art Unit	1654	
(Use as many sheets as necessary) (Use as many sheets as necessary)			ets as necessary)	Examiner Name	Julie Ha	
Sheet	: 4		5	Attorney Docket Number	23558-023USNATL	

NON PATENT LITERATURE DOCUMENTS B48 Osapay, G.; Taylor, J. W. J. Am. Chem. Soc. 1992, 114, 6966 B49 Yu, C.; Taylor, J. W. Tet Lett. 1996, 37, 1731 B50 Geistlinger T. R.; Guy, R. K. J. Am. Chem. Soc. 2001, 123, 1525 Schafmeister, C. E.; Po, J.; Verdine, G. L. J. Am. Chem. Soc. 2000, 122, 5891 B51 Blackwell, H. E.; Sadowsky, J. D.; Howard, R. J.; Sampson, J. N.; Chao, J. A.; B52 Steinmetz, W. E.; O'Leary, D. J.; Grubbs, R. H. J. Org. Chem. 2001, 66, 5291 Judice, J. K.; Tom, J. Y. K.; Huang, W.; Wrin, T.; Vennari, J.; Petropoulos, C. J.; B53 McDowell, R. S. Proc. Natl. Acad. Sci. 1997, 94, 13426 **B54** Orner, B. P.; Ernst, J. T.; Hamilton, A. D. J. Am. Chem. Soc. 2001, 123, 5382 Kutzki, O.; Park, H. S.; Ernst, J. T.; Orner, B. P.; Yin, H.; Hamilton, A. D. J. Am. B55 Chem. Soc. 2002, 124, 11838 Ernst, J. T.; Becerril, J.; Park, H. S.; Yin, H.; Hamilton, A. D. Angew Chem. Int. Edit. B56 *2003*, 42, 535 B57 Kemp, D. S.; Curran, T. P.; Davis, W. M.; Boyd, J. G.; Muendel, C. Journal of *Organic Chemistry* **1991,** *56*, 6672-6682 Kemp, D. S.; Rothman, J. H. Tetrahedron Letters 1995, 36, 4019-4022 B58 Kemp, D. S.; Rothman, J. H. Tetrahedron Letters 1995, 36, 4023-4026 B59 Kemp, D. S.; Rothman, J. H.; Curran, T. C.; Blanchard, D. E. Tetrahedron Letters B60 **1995**, 36, 3809-3812 Kemp, D. S.; Rothman, J. H. Tetrahedron Letters 1995, 36, 3813-3816 B61 Kahn, M.: Kim, H.-O.: Urban, J.: Molecumetics Ltd.: United States, 1999; Vol. B62 5859184 Cabezas, E.; Satterthwait, A. C. J. Am. Chem. Soc. 1999, 121, 3862-3875. (hard copy B63 supplied) Lyu, P. C.; Sherman, J. C.; Chen, A.; Kallenbach, N. R. Proc. Natl. Acad. Sci. U. S. A. B64 **1991**, *88*, 5317-5320 Zhang, C.; Miller, W.; Valenzano, K. J.; Kyle, D. J. Journal of Medicinal Chemistry B65 *2002*, 45, 5280-5286 Garcia-Echeverria, C.; Chene, P.; Blommers, M. J. J.; Furet, P. Journal of Medicinal B66 Chemistry 2000, 43, 3205-3208 Bryant, S. D.; Guerrini, R.; Salvadori, S.; Bianchi, C.; Tomatis, R.; Attila, M.; Lazarus, B67 L. H. Journal of Medicinal Chemistry 1997, 40, 2579-2587 Leduc, A.; Trent, J. O.; Wittliff, J. L.; Bramlett, K. S.; Briggs, S. L.; Chirgadze, N. Y.; B68 Wang, Y.; Burris, T. P.; Spatola, A. F. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 11273-11278 Houston, M. E.; Gannon, C. L.; Kay, C. M.; Hodges, R. S. Journal of Peptide Science B69 **1995,** *1*, 274-282 Tian, Y.; Ramesh, C. V.; Ma, X.; Naqvi, S.; Patel, T.; Cenizal, T.; Tiscione, M.; Diaz, K.; Crea, T.; B70 Arnold, E.; Arnold, G. F.; Taylor, J. W. Journal of Peptide Research 2002, 59, 264-276 Blackwell, H. E.; Grubbs, R. H. Angewandte Chemie-International Edition 1998, 37, 3281-3284 B71 B72 Fairlie DP. Abbenante G. March DR: Macrocyclic peptidomimetics - forcing peptides

Approved for use through 09/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE o a collection of information unless it contains a valid OMB control number.

	Under the Fa	perwork n	reduction Act of 1995, no persons are requ	ned to respond to a concerion of	i information diffess it contains a valid OND control number.	
Substitute fo	stitute for form 1449/PTO			Complete if Known		
				Application Number	10/593,407	
	INFORMAT	ION I	DISCLOSURE	Filing Date	September 19, 2006	
ı			APPLICANT	First Named Inventor	David P. Fairlie	
			Al I LIOAN	Art Unit	1654	
(Use as many sheets as necessary) (Use as many sheets as necessary)				Examiner Name	Julie Ha	
Sheet	5		5	Attorney Docket Number	23558-023USNATL	

NON PATENT LITERATURE DOCUMENTS

		into bioactive conformations. Curr. Med. Chem. 1995, 2: 654-686
	B73	Stradley, S.; Rizo, J.; Bruch, M.; Stroup, A.; Gierasch, L. Biopolymers, 1990, 29, 263
	B74	Toniolo, C. Int. J. Peptide Protein Res. 1990, 35, 287
	B75	Schiller, P. W. in Medicinal Chemistry for the 21st Century, Wermuth, C. G. (ed.)
		IUPAC/Blackwell, London, 1992, pp. 215-232
	B76	Kemp, D. S. in Medicinal Chemistry for the 21st Century, Wermuth, C. G. (ed.)
		IUPAC/Blackwell, London, 1992, pp. 259-277
	B77	Kessler, H.; Diefenbach, B.; Finsinger, D.; Geyer, A.; Gurrath, M.; Goodman, S. L.;
		Hoelzemann, G.; Haubner, R.; Jonczyk, A.Lett. Pept. Sci. 1995, 2, 155
	B78	Marraud, M.; Aubry, A. Biopolymers 1996, 40, 45
	B79	XM.Cheng, S, S. Nikam, Doherty, A. M. Curr. Med. Chem. 1994 , 1, 271
	B80	Holzemann, G. Kontakte (Darmstadt) 1991, 1, 3-12; 2, 55
	B81	Zhang LH, Pesti JA, Costello TD, Sheeran PJ, Uyeda R, Ma P, Kauffman GS, Ward R,
		McMillan JL: An efficient synthesis of cyclic RGD peptides as antithrombotic agents.
		J. Org. Chem. 1996, 61:5180-5185
	B82	Haubner R, Finsinger D, Kessler H: Stereisomeric peptide libraries and
		peptidomimetics for designing selective inhibitors of the D v03 integrin for a new
		cancer therapy. Angew. Chem., Int. Ed. Engl. 1997, 36:1374-1389
	B83	White HD: Unmet therapeutic needs in the management of acute ischemia. Am. J.
		Cardiology 1997 , 80:B2-B10
	B84	Finch, A. M.; Wong, A. K.; Wadi, S. K.; Paczkowski, N. J.; Fairlie, D. P.; Taylor, S.
		M. Low Molecular Weight Peptidic and Cyclic Antagonists of the Receptor for the
		Complement Factor C5a, J. Med. Chem. 1999, 42, 1965-1974
	B85	McDonnel PA, Caldwell GW, Leo GC, Podlogar BL, Maryanoff BE: NMR three
		dimensional solution structure of the serine protease inhibitor cyclotheonamide A.
		Biopolymers 1997, 41: 349-358
	B86	Osapay, G., Taylor, J.W., J. Am. Chem. Soc., 1990, 112, 6046-6051
	B87	Condon, S.M. <u>et. al</u> ., J. Am. Chem. Soc., 2000 , 112, 3007-3014
	B88	Calo, G.; Guerrini, R.; Salvadori, S.; Regoli, D. Brit. J. Pharmacol. 2000, 129:1261-83
	B89	Reinscheid, R.K.; Ardati, A.; Monsma Jr, F.J.; Civelli, O. J. Biol. Chem. 1996, 24(14):
		14163-68
	B90	Salvadori, S.; Picone, D.; Tancredi, T.; Guerrini, R.; Spadaccini, R.; Lazarus, L.H.;
		Regoli, D.; Temussi, P.A. Biochem. Biophys. Res. Comm. 1997, 233:640-643
	B91	Marqusee, S.; Baldwin, R.L., <i>Proc. Natl. Acad. Sci. USA.</i> , 1987 , <i>84</i> , 8898-8902
examiner ignature		Date Considered
15name		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this

form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden,